Aardvark Therapeutics (AARD) Competitors $13.30 -0.63 (-4.52%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AARD vs. SDGR, HROW, SNDX, EVO, AVDL, ZYME, TSHA, ORIC, SION, and XERSShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Schrodinger (SDGR), Harrow (HROW), Syndax Pharmaceuticals (SNDX), Evotec (EVO), Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME), Taysha Gene Therapies (TSHA), Oric Pharmaceuticals (ORIC), Sionna Therapeutics (SION), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. Its Competitors Schrodinger Harrow Syndax Pharmaceuticals Evotec Avadel Pharmaceuticals Zymeworks Taysha Gene Therapies Oric Pharmaceuticals Sionna Therapeutics Xeris Biopharma Aardvark Therapeutics (NASDAQ:AARD) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Is AARD or SDGR more profitable? Aardvark Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -76.22%. Aardvark Therapeutics' return on equity of 0.00% beat Schrodinger's return on equity.Company Net Margins Return on Equity Return on Assets Aardvark TherapeuticsN/A N/A N/A Schrodinger -76.22%-45.70%-24.81% Do analysts recommend AARD or SDGR? Aardvark Therapeutics presently has a consensus price target of $31.43, suggesting a potential upside of 136.31%. Schrodinger has a consensus price target of $26.29, suggesting a potential upside of 29.42%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Aardvark Therapeutics is more favorable than Schrodinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75Schrodinger 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Do institutionals and insiders hold more shares of AARD or SDGR? 79.1% of Schrodinger shares are held by institutional investors. 21.0% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation and earnings, AARD or SDGR? Aardvark Therapeutics has higher earnings, but lower revenue than Schrodinger. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAardvark TherapeuticsN/AN/A-$20.59MN/AN/ASchrodinger$237.92M6.28-$187.12M-$2.48-8.19 Does the media favor AARD or SDGR? In the previous week, Schrodinger had 1 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 4 mentions for Schrodinger and 3 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.61 beat Schrodinger's score of 0.19 indicating that Aardvark Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Schrodinger 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAardvark Therapeutics beats Schrodinger on 8 of the 12 factors compared between the two stocks. Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$288.61M$3.38B$6.13B$10.46BDividend YieldN/A2.30%5.73%4.78%P/E RatioN/A22.9385.1527.20Price / SalesN/A440.31573.26177.33Price / CashN/A46.1137.3961.86Price / BookN/A10.5012.396.65Net Income-$20.59M-$52.47M$3.32B$276.79M7 Day Performance-19.83%-0.99%-0.24%-1.51%1 Month Performance29.63%14.50%9.56%5.45%1 Year PerformanceN/A13.92%71.66%36.24% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark Therapeutics3.6978 of 5 stars$13.30-4.5%$31.43+136.3%N/A$288.61MN/A0.0018Short Interest ↑SDGRSchrodinger2.5707 of 5 stars$19.08-7.6%$26.29+37.8%+16.8%$1.40B$237.92M-7.69790Analyst ForecastHROWHarrow2.9297 of 5 stars$37.48-7.6%$68.50+82.8%-26.3%$1.39B$227.66M-149.92180Positive NewsHigh Trading VolumeSNDXSyndax Pharmaceuticals3.6326 of 5 stars$16.06-0.9%$39.22+144.2%-23.8%$1.38B$23.68M-4.13110News CoverageAnalyst ForecastEVOEvotec1.6209 of 5 stars$3.87-1.8%$7.00+80.9%+35.5%$1.37B$777.33M0.004,827AVDLAvadel Pharmaceuticals2.713 of 5 stars$14.00-1.4%$20.86+49.0%+14.8%$1.36B$169.12M-466.6770ZYMEZymeworks2.4956 of 5 stars$18.06+6.7%$22.50+24.6%+33.7%$1.36B$122.87M-12.04460Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeTSHATaysha Gene Therapies2.2426 of 5 stars$4.88-2.4%$9.00+84.4%+173.8%$1.33B$8.10M-14.35180ORICOric Pharmaceuticals4.2062 of 5 stars$13.68-2.8%$17.29+26.4%+46.0%$1.33BN/A-7.2480Gap UpHigh Trading VolumeSIONSionna Therapeutics1.8284 of 5 stars$29.42+3.8%$38.00+29.2%N/A$1.30BN/A0.0035News CoverageInsider TradeGap DownHigh Trading VolumeXERSXeris Biopharma2.9933 of 5 stars$7.99-2.4%$7.08-11.3%+207.0%$1.29B$246.03M-38.05290News CoverageAnalyst Upgrade Related Companies and Tools Related Companies SDGR Alternatives HROW Alternatives SNDX Alternatives EVO Alternatives AVDL Alternatives ZYME Alternatives TSHA Alternatives ORIC Alternatives SION Alternatives XERS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AARD) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe Final DisplacementA new documentary called The Final Displacement is stirring major controversy — and for good reason. It expose...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
